2026 Interim report
Filed with HKEX · Stock code 2096 · · 93 pages · English
2 Company Overview 4 Corporate Information 6 Financial Highlights 7 Management Discussion and Analysis 37 Corporate Governance and Other Information 50 Independent Auditor’s Review Report 51 Consolidated Statement of Profit or Loss 52 Consolidated Statement of Profit or Loss and Other Comprehensive Income 53 Consolidated Statement of Financial Position 55 Consolidated Statement of Changes in Equit
Simcere Pharmaceutical Group Limited on 6ix
Earlier from Simcere Pharmaceutical
- (Revised) Next Day Disclosure Return
- Simcere Zaiming Enters Exclusive License Agreement with Roche for SIM0660 Global Development
- Simcere Pharmaceutical Enters into a Research Collaboration Agreement with Stanford Medicine to Develop Innovative Therapies for Patients with Idiopathic Pulmonary Fibrosis
- Boehringer Ingelheim and Simcere partner to advance a dual-target antibody treatment to address unmet needs in inflammatory bowel disease
- Simcere's IL-2 Mutant Fusion Protein SIM0278 Entered Phase II Clinical Trial Stage
Later from Simcere Pharmaceutical
- Notification letter and reply form to registered shareholders: notice of publication of interim report 2026
- Notification letter and reply form to non-registered holders: notice of publication of interim report 2026
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
- Next Day Disclosure Return
Follow Simcere Pharmaceutical into a list and get an email when it puts out news.
Follow Simcere Pharmaceutical